Bitcoin price today: falls to 2-week low below $113k ahead of Fed Jackson Hole
In a recent 8-K filing with the Securities and Exchange Commission, Geron (NASDAQ:GERN) Corporation, a biopharmaceutical company specializing in oncology treatments with a market capitalization of $952 million, announced the approval of amendments to its equity incentive and employee stock purchase plans. The announcement comes as the company’s stock has declined 65% over the past six months, though InvestingPro analysis suggests the stock is currently undervalued. The amendments, which were approved during the company’s annual stockholders meeting on May 21, 2025, include an increase in the number of shares available for issuance.
At the virtual 2025 Annual Meeting, stockholders voted on several key proposals. The first proposal was the election of two Class II directors, Dawn C. Bir and Elizabeth G. O’Farrell, each for a three-year term. The second and third proposals involved amendments to the company’s 2018 Equity Incentive Plan and 2014 Employee Stock Purchase Plan. The approved amendments to the 2018 Equity Incentive Plan will increase the share reserve by 20 million shares, while the 2014 Employee Stock Purchase Plan will see an increase of 6 million shares.
Additionally, stockholders gave a non-binding approval to the compensation of the company’s named executive officers and ratified the selection of Ernst & Young LLP as Geron’s independent registered public accounting firm for the fiscal year ending December 31, 2025.
The details of the voting outcomes for each proposal were also disclosed, providing a transparent view of the stockholders’ decisions. This included the number of votes for and against each director nominee, as well as the number of withheld votes and broker non-votes.
The filing also included exhibits, such as the amended versions of the 2018 Equity Incentive Plan and the 2014 Employee Stock Purchase Plan, which provide further details on the terms and conditions of these plans.
The approval of these amendments by Geron’s stockholders is a significant step for the company as it aims to incentivize and retain its employees through stock-based compensation. The increase in the number of shares available for issuance under these plans reflects Geron’s commitment to its long-term incentive strategy for employees. According to InvestingPro data, the company maintains strong liquidity with a current ratio of 7.87, though it faces challenges with a modest gross profit margin of 8.06%. Analysts project significant revenue growth of 163% for the current fiscal year, suggesting potential opportunities ahead. For deeper insights into Geron’s financial health and growth prospects, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro, which covers over 1,400 US stocks with detailed analysis and actionable intelligence.
This report is based on information contained in a press release statement and the official SEC filing by Geron Corporation.
In other recent news, Geron Corporation reported its first-quarter 2025 earnings, meeting analysts’ expectations with an earnings per share (EPS) of -0.03. However, the company’s revenue fell short, coming in at $39.6 million compared to the anticipated $50.46 million. This revenue miss reflects challenges in meeting market demand and resulted in a net loss of $19.8 million for the quarter. Despite these financial hurdles, Geron noted a 10% growth in demand for its new treatment, RYTELLO, in April. The company is focusing on expanding its commercial field team to bolster market penetration and is planning to launch in selected European countries by 2026. Analysts from firms such as TD Cowen have raised concerns about inventory impacts and demand improvement, while Geron remains optimistic about future growth strategies. Additionally, Geron anticipates conducting an interim analysis for its IMPACT MF trial in the second half of 2026, which could influence future revenue streams. The company maintains a strong cash position with $457.5 million in cash and equivalents as of the end of March 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.